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Abstract
Ocular neovascularisation is a pathological hallmark of some forms of debilitating blindness including diabetic retinopathy,
age related macular degeneration and retinopathy of prematurity. Current therapies for delaying unwanted ocular
angiogenesis include laser surgery or molecular inhibition of the pro-angiogenic factor VEGF. However, targeting of
angiogenic pathways other than, or in combination to VEGF, may lead to more effective and safer inhibitors of intraocular
angiogenesis. In a small chemical screen using zebrafish, we identify LY294002 as an effective and selective inhibitor of both
developmental and ectopic hyaloid angiogenesis in the eye. LY294002, a PI3 kinase inhibitor, exerts its anti-angiogenic
effect in a dose-dependent manner, without perturbing existing vessels. Significantly, LY294002 delivered by intraocular
injection, significantly inhibits ocular angiogenesis without systemic side-effects and without diminishing visual function.
Thus, targeting of PI3 kinase pathways has the potential to effectively and safely treat neovascularisation in eye disease.
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Introduction
Ocular Diseases and Neovascularisation
Functional damage to existing blood vessels and inappropriate
development of new blood vessels are hallmarks of prominent
forms of blindness. In diabetic retinopathy (DR), which affects
,150 million patients, neovascularisation of vessels in the adult
retina occurs [1]. In age-related macular degeneration (AMD),
which is estimated to affect ,8 million US patients and ,20
million patients in US plus Europe, neovascularisation of
capillaries in the choroid layer adjacent to the retina occurs [2].
Ocular neovascularisation associated with retinopathy of prema-
turity (ROP) arises when premature infants are placed into high
oxygen to alleviate respiratory distress. As a consequence,
concomitant regression of the lens-associated hyaloid vasculature
and growth of the nascent retinal vasculature ceases. When
returned to normoxia, the infant retina becomes hypoxic leading
to neovascularisation, persistent hyaloid vasculature and eventual
blindness [3]. Thus, a therapeutic goal for DR and AMD is to
develop agents that inhibit ocular neovascularisation and/or
stabilise existing vessels, without diminishing visual function.
Current Ocular Angiogenesis Treatments
Current interventions for resolving inappropriate growth of
new vessels in the eye include laser treatment or molecular
therapies targeted to vascular endothelial cell growth factor
(VEGF). Although the therapeutic mechanism of action is not
fully understood, laser photocoagulation surgery can halt
neovascularisation and reduce macular oedema [1,4]. Howev-
er, success is partial, requires multiple treatments and side
effects include cataracts, hemorrhage, retinal detachment and
visual field loss.
Variations of VEGF molecular therapy to inhibit ocular
neovascularisation include antibodies, siRNAs or small molecule
inhibitors [5–10]. Those in clinical use are antibodies targeted to
VEGF (e.g. bevacizumab (AvastinH) and randizumab (LucentisH))
which delay the growth of new vessels and delay vision loss.
Treatment also requires intraocular injection by retinal specialists,
repeat administrations and patient sedation. Concerns regarding
the development of siRNAs to VEGF have also arisen as they may
act non-specifically [7]. More general concerns regarding the
strategy of solely targeting VEGF include, the observed compen-
satory up-regulation of other pro-angiogenic factors which
decrease therapeutic efficacy, and the potential to cause retinal
neurodegeneration by inhibiting VEGF’s neuroprotectant func-
tion [11,12].
Alternative Anti Angiogenic Targets
Targeting angiogenic molecules other than, or in addition to
VEGF, may reveal more effective and safer inhibitors of
intraocular neovascularisation. Potential targets include growth
factors (e.g. angiopoietin, FGF, HGF, IGF-1, PDGF-B, PlGF),
chemokines (e.g. IL8, SDF1, G-CSF), receptors (e.g. CXCR1, FGF-
R, PlGFR, PDGFR, Tie-receptors), intracellular mediators (e.g.
c-kit kinase, PI3 kinase, PKC) and extracellular mediators (e.g.
integrins, cadherins) [13].
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7867Several drugs which do not selectively target VEGF have indeed
shown anti-angiogenic efficacy in eyes. Pazopanib, PKC412 and
TG100572 are small molecule inhibitors that each targets multiple
kinases [6,9,14]. Pazopanib (ArmalaH) which blocks PDGFRs, c-
Kit, FGFR and c-fms, and TG100572, which inhibits FGF, PDGF
and VEGF, both suppress choroidal neovascularisation in mouse
models [6,9]. TG100572 has improved delivery features as it is
effective following local administration as eye drops [6]. PKC412
blocks PKC, VEGF-R, PDGF-R and SCF-R isoforms, and in
diabetics is reported to reduce macular oedema [14]. However,
liver toxicity was observed following oral administration.
Another approach is to selectively target a distinct pro-
angiogenic molecule. Indeed recent studies report that the
broad-spectrum PI3K inhibitor LY294002 and the avb3/avb5
integrin antagonist EMD478761 suppress retinal or choroidal
neovascularisation following intraocular injection in rodents
[15,16]. A combination of both approaches involves targeting
multiple foci of pro-angiogenic pathways with several selective
inhibitors. Dorrell et al. report that combination angiostatic
therapy with a VEGF aptamer, an integrin antagonist and a
proteolytic fragment of tryptophan tRNA synthetase inhibits
ocular angiogenesis [11].
Zebrafish Intraocular Vasculature and Chemical Screens
We recently demonstrated that the inner retina of zebrafish is
nourished by an intricate vascular network which shares many
features with human hyaloid and retinal vasculatures [17]. Initially
this intraocular vasculature presents as a hyaloid vasculature more
tightly associated with the lens which in adults has migrated to
firmly attach to the inner retina. We identified a cohort of genes
necessary for normal hyaloid vasculature formation in zebrafish
[17]. In addition to amenability towards genetic screens, zebrafish
are also suitable for pharmacological screens [18,19]. In relation to
intraocular vasculature, Cao et al. recently show that exposure of
adult zebrafish to hypoxia combined with treatment with a notch
signaling inhibitor is sufficient to induce retinal neovascularisation
[20]. In a random screen of small molecules, Kitambi et al. recently
identified novel molecules inhibiting hyaloid angiogenesis in
zebrafish larvae [21].
Summary
Here, we conduct a targeted screen of known regulators of
angiogenesis to identify drugs that inhibit developmental angio-
genesis in the zebrafish eye. LY294002, a small molecule inhibitor
of PI3 kinase was identified as an effective inhibitor of
developmental angiogenesis in the eye. LY294002 inhibits new
vessel growth without any apparent effect on existing vessels. The
anti-angiogenic effect of LY294002 is dose-dependent and can be
phenocopied using an inhibitor to AKT, which itself is known to
act downstream of PI3K. Importantly, intraocular administration
of LY294002 selectively inhibits angiogenesis in the eye but does
not diminish visual function.
Methods
Ethics Statement
All experiments were carried out under ethical approval granted
by the UCD animal research ethics committee (http://www.ucd.
ie/researchethics/arec.html).
Drug Treatment
Tg(fli1:EGFP) zebrafish were maintained according to standard
procedures on a 14 h light/10 h dark cycle at 28uC. Embryos
were obtained by natural spawning and developmental stages
established by time and morphological criteria. At 24 hpf, 5
embryos per well were placed in 400 ml of Embryo Medium/1%
DMSO and incubated with drug at 28uC on a 14 h light/10 h
dark cycle [22]. Larvae were euthanised, and fixed in 4% PFA at
4uC overnight before analysis.
Quantification of Primary Branch Number
Prior to analysis of the intraocular vasculature, control- and
treated-larvae were screened under an Olympus SZX16 micro-
scope for general malformations. The overall patterning of the fin,
gut and intersegmental vasculature was examined. Larval lenses
from right eyes were dissected, transferred to depression slides and
observed by epi-fluorescence microscopy using an Olympus
SZX16, or placed in petri-dishes with cover-slip bottoms for
confocal microscopy using a Zeiss UV510 META LSM. To
orientate, lenses were embedded in 10% methyl-cellulose and
manipulated with a 0.5 mm tungsten needle. Number of primary
branches radiating from optic disc at the back of lens was
determined for each specimen (see white arrows in Fig. 1).
Regenerative Angiogenesis Assay
Adult Tg(fli1:EGFP) zebrafish were anesthetised in 0.02%
Tricaine (Sigma) and caudal, dorsal or anal fins amputated with
a scalpel below the second branch points. Fish were incubated in
tank water or tank water/10 mM LY294002 (Sigma) for 9 days,
euthanised in 0.04% Tricaine, decapitated and fixed in 4% PFA
(Sigma) for 24 hours at 4uC. Fins were mounted on glass slides in
VectaShield (Vector) and visualised on an Olympus S2X12
fluorescent microscope. Images were acquired using a Hamamatsu
ORCA-ER camera with OpenLab capturing software and
adapted for publication in Photoshop CS2 9.02.
Electroretinography
Electroretinograms (ERGs) were performed on Tg(fli1:EGFP)
zebrafish treated from 2–5 dpf with 10 mM LY294002 (n=15) or
1% DMSO vehicle (n=13). ERGs were performed in vivo during
the afternoon as described by Fleisch et al., with a few
modifications [23]. Larvae were paralysed with 0.5 mg/ml
mivacurium chloride (MivacronH) and the recording electrode
filled with 0.9% saline. A Kodak projector containing a 300W
halogen light source was used for light stimulation. The
unattenuated irradiance stimulus was 2.8610
3 mW/cm
2. Three
optical density filters were used to produce flash intensities of 23.0
log, 22.0 log and 21.0 log together with the unattenuated
stimulus, 20 log. Flash duration was 100 milliseconds for all
intensities, with an interstimulus interval of between 10 seconds
and 1 minute, depending on flash intensity. To digitise and
visualise data, a NIDAQ 6024E board (National Instruments) and
Windows Whole Cell Programme software (WinWCP V3.9.1;
courtesy of John Dempster, Strathclyde University, Scotland) were
used. Data shown are signal averages of 2–10 responses. The a-
wave was measured from baseline to the trough of the a-wave, and
the b-wave was measured from the trough of the a-wave to the
peak of the b-wave. Raw data from the sample groups were
compared using an independent 2-sample t-test with unequal
variances.
Visual Behaviour Assay
Visual function was assessed by the optokinetic-response (OKR)
assay [24]. Briefly, 5 dpf larvae in Embryo Medium/9% methylcel-
lulose were placed inside a black and white striped drum. The drum
was rotated for 30 seconds in clockwise then counterclockwise
directions and the number of eye saccades counted.
PI3K in Retinal Angiogenesis
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Larvae were euthanised with a lethal dose of Tricaine and fixed
in 0.1 M Sorensen phosphate buffer (pH 7.3)/4% PFA/2.5%
glutaraldehyde overnight at RT. Larvae were post-fixed in 0.1 M
Sorensen phosphate buffer/1% osmium tetroxide for 1 hour at
RT, dehydrated in ascending concentrations of alcohol to 100%
and embedded in Epon resin using standard methods [25]. 1 mm
sections were stained for 20 seconds with toluidine-blue, and
examined by light microscopy using a Leica DMLB bright field
illumination microscope and a Leica DFC 480 camera.
Intraocular Drug Treatments
Tg(fli1:EGFP) larvae were anesthetised with 0.02% Tricaine,
dechorionated and transferred to 3 cm Petri dishes containing
1 ml of cold-liquid CyGEL
TM (Biostatus). Larvae were immobi-
lised in CyGEL at room temperature with the left eye facing
upwards for injection (Fig. S1). Immobilised larvae were injected
in the left eye at 1 or 2 dpf with 10 mM LY294002 or 1% DMSO
diluted in ddH2O/1% FastRed tracer dye using heat pulled glass
capillaries (bore diameter OD/ID: 1/0.58 mm). After intraocular
injection, larvae were retrieved by placing the dish on a chilled ice
pad to melt the CyGEL and immediately transferred to Embryo
Medium at RT for recovery. Larvae were maintained at 28uC
until 5 dpf and hyaloid vasculature analysed as described above.
Results
LY294002 Inhibits Developmental Angiogenesis of the
Eye
To identify drugs that significantly alter development of new
blood vessels in the eye, we performed a small pharmacological
screen in zebrafish. The drugs screened (Table S1) are known to
control growth factor-, cytokine- or inflammatory-mediated
angiogenesis in other tissues, and several are used clinically to
treat AMD, cancer or rheumatoid arthritis [26–28]. Tg(fli1:EGFP)
larvae which specifically express EGFP in all blood vessels [29]
were immersed in drug from 1–5 days post fertilisation (dpf) and
the integrity of the hyaloid vasculature determined by fluorescent
microscopy of dissected lenses.
None of the growth factors, cytokines or antibodies affect the
number of primary branches of hyaloid vasculature (Fig. 1A).
Figure 2. LY294002 results in dose-dependent inhibition of
intraocular angiogenesis. 1 dpf Tg(fli1:EGFP) larvae were treated
with LY294002 at concentrations ranging from 2.5–20 mM and the
number of primary branches of hyaloid vessels determined at 5 dpf.
The data graphed is plotted as the average and standard deviation of 3
replicate experiments. LY294002 results in a statistically significant
inhibition of hyaloid vasculature development (***p,0.001, t-test).
doi:10.1371/journal.pone.0007867.g002
Figure 1. Screens reveal LY294002 to inhibit developmental
angiogenesis in the eye. A. Known regulators of vasculature
formation were screened for effects on developmental angiogenesis
of the hyaloid vasculature in vivo. 1 day post fertilisation (dpf)
Tg(fli1:EGFP) larvae were treated with the indicated drugs and the
number of primary branches of hyaloid vessels determined at 5 dpf.
The drugs used are: recombinant VEGF (VEGF), 50 ng/ml; Tumor
Necrosis Factor (TNF), 20 ng/ml; Adalimumab - HumiraH (Hum), 5 mg/
ml; Infliximab (Inflix), 5 mg/ml; anti-EGF (a-EGF), 5 mg/ml; Bevacizumab-
AvastinH,5mg/ml; Oncostatin M (OSM), 10 ng/ml; Interleukin 1 beta (IL-
1B), 10 ng/ml; Nacyselyn (NAL), 10 mM; and LY294002 (LY), 10 mM. The
data is plotted as the average and standard deviation of 3 replicate
experiments. LY294002 results in a statistically significant inhibition of
hyaloid vasculature development (***p,0.001, t-test). B–C. Fluorescent
images illustrating the integrity of GFP-positive blood vessels at 5 dpf in
LY294002-treated and DMSO-treated controls. No differences are
observed in the morphology of the trunk vessels (B), whereas the
hyaloid vessel branching pattern is abnormal and the branch number is
reduced (C). White arrows in C indicate the primary branches radiating
from the optic disc at the back of the lens.
doi:10.1371/journal.pone.0007867.g001
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the number of primary branches of hyaloid vasculature, indicative
of anti-angiogenic activity (Fig. 1A). Analysis of wholemount
larvae suggests that LY294002 treatment has no significant effect
on the intersegmental or trunk vessels (Fig. 1B), which develop
earlier than the hyaloid vasculature [17,29]. Confocal analysis
Figure 3. Time-dependent inhibition of intraocular, developmental angiogenesis by LY294002. Tg(fli1:EGFP) larvae were treated with
10 mM LY294002 for the indicated time frames and the number of primary branches of hyaloid vessels determined at 5 dpf. The data is plotted as the
average and standard deviation of 3 replicate experiments. 10 mM LY294002 is added for 24 hours (A) or 48 hours (B) starting at 1, 2, 3 or 4 dpf. In C
10 mM LY294002 is added at 1 dpf for 96, 72, 48 or 24 hours. In any experimental variation, the presence of LY294002 from 2–3 dpf is sufficient to
result in a statistically significant inhibition of developmental angiogenesis of hyaloid vessels (*p,0.05; ***p,0.001, t-test).
doi:10.1371/journal.pone.0007867.g003
Figure 4. The Akt inhibitor SH6 phenocopies the PI3K inhibitor LY294002. Comparison of hyaloid vasculature patterning in DMSO-treated
control larvae (A), 10 mM LY294002 treated larvae (B) and larvae treated with the Akt inhibitor SH6 at 10 mM( C). All larvae are from the Tg(fli1:EGFP)
line and were treated from 1–5 dpf. Like LY294002, SH6 affects angiogenesis of the hyaloid vessels. Abnormal patterning of the hyaloid vasculature is
observed with SH6 (C) resembling LY294002-treated larvae (B), though no significant reduction in primary vessel number is observed with SH6 (D).
The data shown in panel D is plotted as the average and standard deviation of 3 replicate experiments (***p,0.001, t-test).
doi:10.1371/journal.pone.0007867.g004
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reduces the branch number and patterning of the hyaloid
vasculature (Fig. 1C). This result suggests that the PI3K inhibitor,
LY294002, inhibits the formation of new vessels but does not
reduce the number of existing vessels systemically.
Dose- and Time-Dependent Inhibition of Intraocular
Angiogenesis by LY294002
Treating larvae from 1–5 dpf, with a range of LY294002
concentrations, reveals a dose-dependent inhibition of hyaloid
vessel angiogenesis with an IC50 of ,12 mM (Fig. 2).A t
concentrations from 7.5–12.5 mM LY294002, statistically
significant inhibition of hyaloid angiogenesis is observed in
the absence of gross morphological defects. Larvae incubated
in 10 mM LY294002 occasionally display mild oedema
indicative of systemic side effects. At concentrations of
17.5 mM LY294002 and above, systemic toxic effects including
oedema, bent body axis and craniofacial abnormalities are
observed. Thus, 10 mM LY294002 was utilised for all
additional experiments.
To determine if LY294002 inhibits hyaloid angiogenesis during
a specific developmental time-frame, 1–4 dpf Tg(fli1:EGFP) larvae
were treated for 24, 48, 72 or 96 hours, and hyaloid vasculature
analysed at 5 dpf (Fig. 3). If LY294002 is added to 1 or 4 dpf
larvae for 24 hours, development of the hyaloid branches is
unaffected (Fig. 3 A & C). However, the presence of LY294002
Figure 5. LY294002 attenuates ectopic developmental angiogenesis in obd mutants. Wildtype Tg(fli1:EGFP) larvae (wt) or out of bounds
mutants in the Tg(fli1:EGFP) background (obd) were treated with 10 mM LY294002 from 1–5 dpf before dissecting lenses and analysing hyaloid
vasculature development. LY294002 inhibits normal developmental angiogenesis in wildtype Tg(fli1:EGFP) larvae as seen by the reduced vessel
patterning in lateral views of the lens (A, D). LY294002 also inhibits the extraneous hyaloid branch patterning (B) and branch number (C) observed in
obd mutants as observed by reduction of branch patterning to near normal levels (E and F). Arrows depict the orientation of the lens, pointing in the
direction from the optic disk to lens. G) Quantification of the reduction in the extraneous primary hyaloid branches number in LY294002-treated obd
mutants. The data is plotted as the average and standard deviation of larvae (obd
2/2 n=7,obd
2/2 treated: n=8) from 2 independent experiments
(***p,0.001, t-test). OD: Optic Disc.
doi:10.1371/journal.pone.0007867.g005
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inhibition of hyaloid angiogenesis. These results are consistent
with LY294002 blocking developmental angiogenesis of new
hyaloid vessels but exerting no effect on existing intraocular
vessels.
The PI3K-Akt Pathway Controls Hyaloid Angiogenesis
To corroborate the anti-angiogenic activity of LY294002 on
hyaloid vasculature being mediated via inhibition of PI3K
signalling, we selectively inhibited the activity of Akt/PKB, a
downstream target of PI3K [30]. Analysis of hyaloid vessels at
5 dpf demonstrates that SH6, a PKB/Akt inhibitor, can
phenocopy LY294002. Both drugs at 10 mM, result in a striking
difference in the patterning of hyaloid vessels (Fig. 4 A–C).
Interestingly, LY294002, but not SH6, also significantly reduces
the number of primary hyaloid vessels (Fig. 4 D).
LY294002 Attenuates Ectopic and Regenerative
Angiogenesis
The ability of LY294002 to inhibit extraneous angiogenesis was
determined in out of bounds (obd) mutants. As a consequence of a
recessive mutation in plexin D, obd
2/2 larvae present with ectopic
developmental angiogenesis [17,31]. Treatment of obd
2/2 larvae
with 10 mM LY294002 inhibits ectopic hyaloid angiogenesis and
can reduce branch patterning to near wild type levels (Fig. 5).
The anti-angiogenic efficacy and safety of LY294002 in the
context of adult tissues was determined using a fin regeneration
assay [32]. The extent of angiogenesis in regenerating fins was
determined in adult fish following caudal, dorsal or anal fin
clipping. Compared to controls, LY294002 significantly inhibits
regenerative angiogenesis (Fig. 6 and Fig S2). LY294002 also
inhibits regeneration length, which is reported to be angiogenesis-
dependent [32] (Fig. 6 and Fig S2). Otherwise, no toxic effects
were observed, and LY294002- and control-treated adults were
indistinguishable in relation to behaviour, ventilation rate and
swimming patterns.
LY294002 Inhibits Retinal Angiogenesis without
Affecting Retinal Function
The electroretinogram (ERG) is a diagnostic method for
quantifying outer retinal function. ERGs from larvae treated
with LY294002 or vehicle from 2–5 dpf show equivalent
responses at 4 flash intensities (Fig. 7A–C). At maximum flash
intensity, the a-wave measure of photoreceptor hyperpolarisa-
tion has amplitudes of 22865.8 mVo r23163.5 mV, and
implicit times of 6167.6 milliseconds (ms) or 6867.7 ms in
control and drug-treated larvae, respectively. Similarly, the b-
wave which reflects signal transmission to bipolar cells has
amplitudes of 199620.5 mV or 208628 mV and implicit times
of 157610.5 ms or 169610.1 ms in control and drug-treated
larvae, respectively (Fig. 7A–C). In agreement, the retinal
histology of larvae treated with LY294002 from 2–5 dpf is
indistinguishable from controls. Both samples consist of
laminated retinas with prominent optic nerves and transparent
lenses (Fig. 7D).
Retinal histology in larvae treated earlier from 1–5 dpf does
feature apoptotic nuclei and tissue vacuolation (Fig. 7D).T h i s
is consistent with a loss of visual function in larvae treated with
LY294002 for just 24 hours beginning at 1 dpf and suggests a
role for PI3K in early retinal development, independent of
angiogenesis. In summary, treatment with LY294002 can
block hyaloid angiogenesis with no detrimental effect on
retinal function.
Intraocular LY294002 Selectively Inhibits Angiogenesis
and not Visual Behaviour
Finally, we determined if localised delivery of LY294002 can
inhibit intraocular angiogenesis, and do so without systemic
side-effects, or effects on retinal function. Compared to larvae
injected with vehicle alone, larvae injected with 10 mM
LY294002 do display significant inhibition of hyaloid vessel
angiogenesis (Fig. 8 A, C). Unlike the mild oedema observed
in larvae treated systemically with LY294002, intraocular
injection of LY294002 has no obvious systemic side-effects.
Visual function in larvae injected intraocularly with LY294002
was analysed by the optokinetic response (OKR) [24]. In this
Figure 6. LY294002 attenuates Regenerative Angiogenesis in
Adult Zebrafish. The caudal fins of adult Tg(fli1:EGFP) zebrafish were
amputated and left to regenerate in either tank water or tank water
supplemented with 10 mM LY294002. Bight field micrographs (A)o r
fluorescent micrographs (B) of representative fins at 9 days post-
amputation are shown. The maximal, average blood vessel length in the
regenerated tissue was quantified at the third fin ray in either fin lobe
and the results are depicted in (C). LY294002 significantly inhibits
regenerative angiogenesis in the tail fin (** p,0.01, t-test). Yellow lines
in B indicate the amputation plane. n=8 fin rays in 4 fish. Scale
bars=500 mm.
doi:10.1371/journal.pone.0007867.g006
PI3K in Retinal Angiogenesis
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white stripes via reproducible saccades. No difference is
observed in the OKR response of fish injected intraocularly
with vehicle alone or with LY294002 (Fig. 8B).T h e s er e s u l t s
indicate that intraocular administration of LY294002 can
selectively block angiogenesis in the eye without detrimental
effects on visual function.
Discussion
Summary
We report here evidence demonstrating that the small molecule
inhibitor LY294002 can be an effective and safe inhibitor of ocular
angiogenesis in vivo. LY294002 inhibits normal and extraneous
developmental angiogenesis in the zebrafish eye, in dose- and
time-dependent manners. Systemic administration of LY294002
results in oedema and locomotor activity defects are indicated
(data not shown). However, intraocular administration of
LY294002 can selectively inhibit intraocular angiogenesis without
affecting retinal morphology or visual function.
LY294002- An Ocular Anti-Angiogenic
Does LY294002 or its cellular target have potential for clinical
use as an ocular anti-angiogenic? Our data demonstrates that
LY294002 is an effective inhibitor of hyaloid vasculature
angiogenesis in the zebrafish eye. In addition, recent studies
report that intraocular administration of LY294002 reduces
unwanted retinal and choroidal neovascularisation in murine
models [15,16]. The mouse studies did not address potential effects
of LY294002 on retinal function, but our study shows that short-
term treatment with LY294002 can have no effect on ocular
morphology or visual physiology. LY294002 is most likely exerting
its anti-angiogenic activity by inhibiting the PI3K signalling
pathway, which is known to mediate angiogenesis [30]. Indeed,
LY294002 is a classic, broad-spectrum inhibitor of phosphoino-
sitide 3-kinases (PI3K) [33]. The PI3K enzyme family act as
second messengers during signal transduction events associated
with diverse cellular activities, including migration, proliferation
and differentiation [30]. Recent evidence suggests that LY294002
also inhibits casein kinase, GSK3b and mTOR (a PI3K-related
kinase) [34]. LY294002, however, was previously excluded from
Figure 7. LY294002 inhibits retinal angiogenesis without affecting retinal function. A–C) Electroretinography of control (n=13) and
LY294002-treated (n=15) zebrafish at 5 dpf. Shown is representative data from control (A) and LY294002-treated (B) larval zebrafish in response to
an intensity series of white light stimulation. The stimulus flash was attenuated from 3 log units to unattenuated. The black bars at the bottom
represent stimulus duration. The two groups show similar intensity response curves for the b-wave (C). To generate the intensity response curve, the
average response at the maximum flash intensity was set to 1 and the average response at attenuated flash intensities was normalised to this
(average 6 SEM). D) Histological sections of zebrafish eyes from 5 dpf larvae treated with LY294002 from 1–5 dpf or 2–5 dpf. Retinal histology
appears normal in fish treated from 2–5 dpf showing lamination, presence of optic nerve and similar size/shape to controls. In larvae treated from 1–
5 dpf sparse apoptotic nuclei (arrowheads) and tissue vacuoles are observed (Magnification 4006).
doi:10.1371/journal.pone.0007867.g007
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the broad-spectrum of PI3Ks inhibited, off-target effects or
systemic administration.
Refined Targeting of PI3K Pathways
Our data suggests that LY294002 can have selective anti-
angiogenic effects in the eye following intraocular administration.
No perturbations of retinal function or morphology are observed.
Future studies will need to determine if the lack of toxicity is due to
local administration to the eye, species difference or short-term
treatment.
However, instead of using a broad-spectrum PI3K inhibitor like
LY294002, it should also be possible to selectively interfere with
the subset of PI3K signals associated with pathological angiogen-
esis in the eye. The development of isoform-selective PI3K
inhibitors has already led to their approval for clinical trials in
cancer [35,36]. The PI3K family is divided into several classes
based on protein structure and substrate targets. The signal
transduction mechanism is best understood for Class I PI3Ks [30].
These are heterodimers, comprising of one of four p110 catalytic
subunits (a, b, d or c) plus a regulatory subunit. Growth factor or G
protein-coupled receptor activation recruits the regulatory subunit
of PI3K resulting in activation of the catalytic subunit. Subsequent
conversion of PI(4,5)P2 to PI(3,4,5)P3 promotes the recruitment of
proteins exemplified by AKT to the plasma membrane. AKT is
phosphorylated by phosphoinositide-dependent protein kinases
and targets proteins involved in angiogenesis, apoptosis, cell
growth and glucose uptake [37,38].
Analysis of p110d and c reveals specific roles for these isoforms
in the immune system. Indeed, IC87114, an inhibitor selective for
p110d, was subsequently found to inhibit a form of leukaemia and
is now in clinical trial [39]. Similarly, genetic analyses demonstrate
that the p110a isoform is selectively required for angiogenesis [40].
To our knowledge no p110a-selective inhibitor has gone on to
clinical development. However, several potential p110a selective
inhibitors have been reported [35,39]. Our data with LY294002
strongly support testing the efficacy and safety of p110a-selective
PI3K inhibitors in models of ocular neovascularisation.
An alternative approach to isoform-selective PI3K inhibitors is
the use of a modified version of LY294002. Until recently, it was
generally considered that broad-spectrum PI3K inhibitors would
not have clinical use due to toxicity arising from inhibition of
physiological signalling. However, SF1126 is a modified version
of LY294002 in clinical development for cancer. It consists of
LY294002 linked to a peptide sequence that targets it to the
vasculature [41]. Future studies are warranted to test the efficacy
and safety of this prodrug in models of ocular angiogenesis.
Screens for Ocular Anti-Angiogenics in Zebrafish
Here we provide further proof-of-principle that chemical screens in
zebrafish can uncover novel anti-angiogenic drugs for the eye. The
screens are relatively simple with 5 larvae per well incubated from
1–5 days post-fertilisation with an experimental drug. Assessment
of ocular angiogenesis is facilitated by the using the Tg(fli1:EGFP)
line and a fluorescent dissecting microscope. The limiting step is
the labour-intensive dissection of lenses but this may be overcome
with improvements in imaging in vivo. Kitambi et al. recently
identified several drugs that perturb intraocular angiogenesis in vivo
[21] and our study demonstrates how such drugs can be further
characterised to address specificity and safety. Finally, our screens
Figure 8. Intraocular injection of LY294002 inhibits angiogenesis but not visual function. A) The hyaloid vasculature of 5 dpf larvae
intraocularly injected with 10 mM LY294002 at 2 dpf shows abnormal patterning and reduced numbers of primary branches compared with controls
injected with 1% DMSO (left images are lateral views, and right images are dorsal views of lenses. OD: optic disc; scale bars: 50 mm) B) Graph of the
percentage of 5 dpf larvae with optokinetic responses (OKR) following intraocular injection of LY294002 at 1 or 2 dpf. The Fisher test shows no
statistically significant difference in visual function when LY294002 is injected intraocularly at 1 or 2 dpf (p values shown on table) C) Graph showing
percentage of 5 dpf larvae with normal hyaloid vasculature after injection of LY294002 at 1 or 2 dpf. Intraocular LY294002 at 1 or 2 dpf, significantly
inhibits hyaloid angiogenesis. Data graphed from 3 independent experiments; LY294002 at 1 dpf, n=17; 1% DMSO at 1 dpf, n=9; LY294002 at 2 dpf,
n=26; 1% DMSO at 2 dpf, n=13 (***p,0.001, Chi-Square test).
doi:10.1371/journal.pone.0007867.g008
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antibodies or recombinant proteins had no effect, most likely
due to poor bioavailability in the eye or degradation.
Future Perspectives
In summary, we provide evidence that a broad-spectrum PI3K
inhibitor can attenuate ocular angiogenesis without perturbing
visual function. Thus, there can be cautious optimism about the
potential clinical use of PI3K inhibitors to treat unwanted ocular
neovascularisation. This could involve administration of an
isoform-specific inhibitor or a vasculature-targeted prodrug, either
as monotherapies or part of combination angiostatic therapies.
Supporting Information
Figure S1 Intraocular Injection of LY294002 in zebrafish
larvae. A) ,5 dechorionated zebrafish larvae (48 hpf in the figure)
are immobilized in CyGEL at RT and oriented with left eye facing
upwards. Dechorionation is extremely important as non-dechor-
ionated larvae collapse in contact with CyGEL. B) Intraocular
injection (0.1–0.2 ml/eye) is performed with a heat pulled glass
capillary. C) After intraocular injection the Petri dish is placed on a
chilled ice pad to melt CyGEL and larvae are transferred gently
but immediately to a plate with RT embryo medium for recovery.
Found at: doi:10.1371/journal.pone.0007867.s001 (4.36 MB TIF)
Figure S2 Regenerative angiogenesis in zebrafish dorsal or anal
fins is inhibited by LY294002. The dorsal (A, C and E) or anal fins (B,
Da n dF )o fa d u l tTg(fli1:EGFP) zebrafish were amputated and left to
regenerate in either tank water or tank water supplemented with
10 mM LY294002. Bight field micrographs (A and B) or fluorescent
micrographs (C and D) of representative fins at 9 days post
amputation are shown. The maximal, average blood vessel length
in the regenerated tissue was quantified at the third fin ray from either
side of each image and the resultsare depicted in (E and F). LY294002
significantly inhibits regenerative angiogenesis in both dorsal and anal
fins (***p,0.001; t-test). Yellow lines in C and D indicate the
amputation planes. n=8 fin rays in 4 fish. Scale bars=500 mm.
Found at: doi:10.1371/journal.pone.0007867.s002 (4.74 MB TIF)
Table S1 Pro- and Antiangiogenic drugs screened for effects on
angiogenesis of the zebrafish hyaloid vasculature.
Found at: doi:10.1371/journal.pone.0007867.s003 (0.03 MB
DOC)
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